Mika Skeppholm

1.4k total citations
23 papers, 728 citations indexed

About

Mika Skeppholm is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Mika Skeppholm has authored 23 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 7 papers in Internal Medicine and 5 papers in Hematology. Recurrent topics in Mika Skeppholm's work include Atrial Fibrillation Management and Outcomes (15 papers), Cardiac Arrhythmias and Treatments (7 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Mika Skeppholm is often cited by papers focused on Atrial Fibrillation Management and Outcomes (15 papers), Cardiac Arrhythmias and Treatments (7 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Mika Skeppholm collaborates with scholars based in Sweden, United States and United Kingdom. Mika Skeppholm's co-authors include Leif Friberg, Andreas Terént, Rickard E. Malmström, Jovan P. Antović, Håkan Wallén, Karin Malmqvist, Yuko Rönquist-Nii, Anton Pohanka, Margareta Blombäck and Maria Berndtsson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Annals of the Rheumatic Diseases.

In The Last Decade

Mika Skeppholm

23 papers receiving 709 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mika Skeppholm Sweden 15 584 270 101 94 72 23 728
Cecilia Guillermo Uruguay 9 356 0.6× 252 0.9× 116 1.1× 39 0.4× 69 1.0× 32 554
Miklós Rohla Austria 15 419 0.7× 100 0.4× 32 0.3× 67 0.7× 125 1.7× 54 605
Nina Vene Slovenia 14 334 0.6× 158 0.6× 69 0.7× 40 0.4× 47 0.7× 26 476
Daniel Eriksson Germany 13 293 0.5× 163 0.6× 72 0.7× 73 0.8× 42 0.6× 38 539
Luděk Slavík Czechia 13 169 0.3× 102 0.4× 178 1.8× 74 0.8× 60 0.8× 63 549
Antonia Sambola Spain 11 436 0.7× 85 0.3× 87 0.9× 78 0.8× 150 2.1× 29 622
Jayesh Jani United States 9 144 0.2× 245 0.9× 121 1.2× 68 0.7× 125 1.7× 15 491
Nebojša Antonijević Serbia 11 191 0.3× 123 0.5× 145 1.4× 23 0.2× 68 0.9× 65 430
Ann-Kristin Öhlin Sweden 13 162 0.3× 157 0.6× 247 2.4× 53 0.6× 57 0.8× 22 500
Ron Peters Netherlands 9 403 0.7× 281 1.0× 111 1.1× 39 0.4× 262 3.6× 20 614

Countries citing papers authored by Mika Skeppholm

Since Specialization
Citations

This map shows the geographic impact of Mika Skeppholm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika Skeppholm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika Skeppholm more than expected).

Fields of papers citing papers by Mika Skeppholm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika Skeppholm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika Skeppholm. The network helps show where Mika Skeppholm may publish in the future.

Co-authorship network of co-authors of Mika Skeppholm

This figure shows the co-authorship network connecting the top 25 collaborators of Mika Skeppholm. A scholar is included among the top collaborators of Mika Skeppholm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika Skeppholm. Mika Skeppholm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ząbczyk, Michał, et al.. (2024). Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis. Scandinavian Journal of Clinical and Laboratory Investigation. 84(4). 257–267. 2 indexed citations
2.
Skeppholm, Mika, et al.. (2024). Apixaban plasma concentrations in patients with obesity. European Journal of Clinical Pharmacology. 80(9). 1343–1354. 1 indexed citations
3.
Skeppholm, Mika, et al.. (2024). Apixaban trough concentrations in atrial fibrillation patients with reduced renal function. Biomedicine & Pharmacotherapy. 180. 117613–117613. 1 indexed citations
4.
Skeppholm, Mika, et al.. (2018). Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin‐based trigger. Journal of Thrombosis and Haemostasis. 16(12). 2462–2470. 13 indexed citations
5.
Antovič, Aleksandra, Maria Berndtsson, Agnes Rasmuson, et al.. (2017). Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thrombosis and Haemostasis. 117(9). 1700–1704. 37 indexed citations
6.
Skeppholm, Mika & Leif Friberg. (2016). Usefulness of Health Registers for detection of bleeding events in outcome studies. Thrombosis and Haemostasis. 116(12). 1131–1139. 37 indexed citations
7.
Guðmundsdóttir, Brynja R., C. W. Francis, Robert C. Gosselin, et al.. (2016). A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma. Journal of Thrombosis and Haemostasis. 14(5). 1043–1053. 11 indexed citations
8.
Malmström, Rickard E., Jovan P. Antović, Anton Pohanka, et al.. (2016). Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. European Journal of Clinical Pharmacology. 72(6). 671–679. 28 indexed citations
9.
Skeppholm, Mika, Maria Berndtsson, Faris Al‐Khalili, et al.. (2015). Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thrombosis Research. 136(1). 148–153. 59 indexed citations
10.
Friberg, Leif, Mika Skeppholm, & Andreas Terént. (2015). Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. Journal of the American College of Cardiology. 65(3). 225–232. 140 indexed citations
11.
Skeppholm, Mika, Paul Hjemdahl, Jovan P. Antović, et al.. (2014). On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation. Thrombosis Research. 134(4). 783–789. 42 indexed citations
12.
Skeppholm, Mika & Leif Friberg. (2014). Adherence to warfarin treatment among patients with atrial fibrillation. Clinical Research in Cardiology. 103(12). 998–1005. 49 indexed citations
13.
Antović, Jovan P., Mika Skeppholm, Liselotte Onelöv, et al.. (2013). Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. European Journal of Clinical Pharmacology. 69(11). 1875–1881. 91 indexed citations
14.
Skeppholm, Mika, Fariborz Mobarrez, Karin Malmqvist, & Håkan Wallén. (2012). Platelet-derived microparticles during and after acute coronary syndrome. Thrombosis and Haemostasis. 107(6). 1122–1129. 59 indexed citations
15.
Agewall, Stefan, Maria Daniel, Christina Ekenbäck, et al.. (2011). Risk Factors for Myocardial Infarction With Normal Coronary Arteries and Myocarditis Compared With Myocardial Infarction With Coronary Artery Stenosis. Angiology. 63(7). 500–503. 28 indexed citations
16.
Skeppholm, Mika, Anders Kallner, Karin Malmqvist, Margareta Blombäck, & Håkan Wallén. (2011). Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?. Thrombosis Research. 128(5). 483–489. 30 indexed citations
17.
Skeppholm, Mika, Anders Kallner, Majid Kalani, et al.. (2009). ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus. Blood Coagulation & Fibrinolysis. 20(8). 619–626. 15 indexed citations
18.
Skeppholm, Mika, N. Håkan Wallén, Margareta Blombäck, & Anders Kallner. (2008). Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?. Clinical Chemistry and Laboratory Medicine (CCLM). 46(8). 1175–9. 17 indexed citations
19.
Skeppholm, Mika, N. Håkan Wallén, Karin Malmqvist, Anders Kallner, & Jovan P. Antović. (2007). Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome. Thrombosis Research. 121(2). 175–181. 7 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cecilia Guillermo Breakdown of academic impact, for papers by Miklós Rohla Breakdown of academic impact, for papers by Nina Vene Breakdown of academic impact, for papers by Daniel Eriksson Breakdown of academic impact, for papers by Luděk Slavík Breakdown of academic impact, for papers by Antonia Sambola Breakdown of academic impact, for papers by Jayesh Jani Breakdown of academic impact, for papers by Nebojša Antonijević Breakdown of academic impact, for papers by Ann-Kristin Öhlin Breakdown of academic impact, for papers by Ron Peters
Rankless by CCL
2026